OQRO

Feed News

Explore

Insider trades Fund holdings Congress trades Federal contracts

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director received an award of 4,884 GILD derivative securities | OQRO

Insider trades

Insider trade

Director received an award of 4,884 GILD derivative securities

Traded Apr 30, 2026 · Filed May 4, 2026

GILGilead SciencesGILD

4,884
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Apr 30, 2026
Reporting period: Not applicable
Filed with the SEC: May 4, 2026

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001213307-26-000003
Filed / recorded

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

May 4, 2026, 8:22 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

GILEAD SCIENCES, INC.

Issuer CIK

882095

Ticker

GILD

Reporting person

Anthony Welters

Relationship

Director

Security

Non-qualified Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Apr 30, 2026

Transaction code

Shares / units

4,884

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

4,884

Ownership form

Direct

Amendment

Footnotes from the filing

100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Around the same time

CEO sold ~$1.43M of Gilead Sciences

Scheduled in advance4mo ago

CEO sold ~$405K of Gilead Sciences

Scheduled in advance4mo ago

CEO sold ~$138K of Gilead Sciences

Scheduled in advance4mo ago